Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $6.34M | $43.8M |
| Revenue growth | — | — | — | — | — | 589.9% |
| Operating income | -$54.6M | -$75.0M | -$89.1M | -$79.1M | -$60.6M | -$42.0M |
| Operating margin | — | — | — | — | -954.9% | -95.9% |
| Net income | -$55.2M | -$75.8M | -$88.2M | -$76.4M | -$58.2M | -$35.0M |
| Net margin | — | — | — | — | -918.0% | -80.1% |
| EPS (diluted) | -$105.42 | -$13.52 | -$3.22 | -$2.78 | -$15.24 | -$4.19 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$36.1M | -$80.8M | -$75.7M | -$68.6M | -$18.4M | -$4.99M |
| Capital expenditures | $2.19M | $1.10M | $1.87M | $486K | $36.0K | $518K |
| Free cash flow | -$38.3M | -$81.9M | -$77.6M | -$69.1M | -$18.4M | -$5.51M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $19.2M | $198M | $120M | $44.7M | $55.3M | $138M |
| Total assets | $36.3M | $218M | $139M | $60.9M | $71.1M | $155M |
| Total liabilities | $41.6M | $32.6M | $33.5M | $24.1M | $53.5M | $119M |
| Shareholders' equity | -$83.3M | $185M | $106M | $36.8M | $17.6M | $35.3M |
| Retained earnings | -$85.1M | -$161M | -$249M | -$326M | -$384M | -$419M |
| Shares (wtd avg diluted) | 524K | 5.61M | 27.4M | 27.5M | 3.82M | 8.36M |
Every figure is extracted from Xilio Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.